Illumina (NASDAQ:ILMN) Given New $139.00 Price Target at Robert W. Baird

Illumina (NASDAQ:ILMN) had its target price upped by Robert W. Baird from $124.00 to $139.00 in a research report report published on Wednesday,Benzinga reports. They currently have a neutral rating on the life sciences company’s stock.

A number of other brokerages have also recently weighed in on ILMN. Barclays upped their price target on shares of Illumina from $135.00 to $145.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 5th. Piper Sandler decreased their price target on shares of Illumina from $200.00 to $195.00 and set an “overweight” rating for the company in a research report on Tuesday, August 13th. StockNews.com began coverage on shares of Illumina in a research report on Thursday, August 29th. They set a “buy” rating for the company. Leerink Partners upped their price target on shares of Illumina from $160.00 to $200.00 and gave the stock an “outperform” rating in a research report on Thursday, October 17th. Finally, Royal Bank of Canada boosted their price objective on shares of Illumina from $252.00 to $254.00 and gave the stock an “outperform” rating in a report on Tuesday, November 5th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, fourteen have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $162.18.

Illumina Stock Down 2.6 %

Shares of NASDAQ ILMN opened at $151.09 on Wednesday. Illumina has a 52-week low of $89.00 and a 52-week high of $156.66. The firm has a fifty day moving average of $138.09 and a 200-day moving average of $123.56. The stock has a market capitalization of $24.07 billion, a PE ratio of -15.17 and a beta of 1.13. The company has a quick ratio of 0.86, a current ratio of 2.43 and a debt-to-equity ratio of 0.94.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.88 by $0.26. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The company had revenue of $1.08 billion during the quarter, compared to analysts’ expectations of $1.08 billion. During the same period in the previous year, the company earned $0.33 EPS. The business’s quarterly revenue was down 3.5% compared to the same quarter last year. On average, analysts anticipate that Illumina will post 4.11 EPS for the current year.

Institutional Investors Weigh In On Illumina

Institutional investors have recently modified their holdings of the business. Industrial Alliance Investment Management Inc. acquired a new stake in shares of Illumina during the 2nd quarter worth approximately $34,000. Versant Capital Management Inc grew its position in shares of Illumina by 292.9% during the 2nd quarter. Versant Capital Management Inc now owns 330 shares of the life sciences company’s stock worth $34,000 after buying an additional 246 shares during the period. Massmutual Trust Co. FSB ADV grew its holdings in Illumina by 65.1% during the third quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company’s stock valued at $56,000 after purchasing an additional 168 shares during the period. Focused Wealth Management Inc acquired a new position in Illumina during the third quarter valued at approximately $63,000. Finally, Hollencrest Capital Management acquired a new position in Illumina during the third quarter valued at approximately $63,000. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.